Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Employees - 61,
CEO - Mr. Scott G. Davis,
Sector - Healthcare,
Country - US,
Market Cap - 8.44M
Altman ZScore(max is 10): -12.58, Piotroski Score(max is 10): 4, Working Capital: $11515000, Total Assets: $27310000, Retained Earnings: $-253592000, EBIT: -10652000, Total Liabilities: $14618000, Revenue: $17544000
- Current Price $0.29 - Analyst Target Price $2.50Ticker | EKSO |
Index | - |
Curent Price | 0.29 |
Change | -12.21% |
Market Cap | 8.44M |
Average Volume | 1.97M |
Income | -10.79M |
Sales | 17.54M |
Book Value/Share | 0.45 |
Cash/Share | 0.28 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 61 |
Moving Avg 20days | -32.77% |
Moving Avg 50days | -31.33% |
Moving Avg 200days | -59.93% |
Shares Outstanding | 28.20M |
Earnings Date | May 05 AMC |
Inst. Ownership | 13.18% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | 0.48 |
Price/Book | 0.65 |
Price/Cash | 1.05 |
Price/FCF | - |
Quick Ratio | 1.77 |
Current Ratio | 2.35 |
Debt/Equity | 0.44 |
Return on Assets | -38.36% |
Return on Equity | -80.71% |
Return on Investment | -64.88% |
Gross Margin | 53.39% |
Ops Margin | -60.67% |
Profit Margin | -61.51% |
RSI | 27.79 |
BETA(β) | 0.94 |
From 52week Low | -9.19% |
From 52week High | -81.01% |
EPS | -0.49 |
EPS next Year | -0.23 |
EPS next Qtr | -0.09 |
EPS this Year | 35.71% |
EPS next 5 Year | 41.87% |
EPS past 5 Year | 25.99% |
Sales past 5 Year | 8.98% |
EPS Y/Y | 49.72% |
Sales Y/Y | -2.06% |
EPS Q/Q | 42.17% |
Sales Q/Q | -10.14% |
Sales Surprise | -27.02% |
EPS Surprise | -9.09% |
ATR(14) | 0.06 |
Perf Week | -35.05% |
Perf Month | -28.81% |
Perf Quarter | -50.70% |
Perf Year | -79.96% |
Perf YTD | -52.36% |
Target Price | 2.50 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer